



# Semi-annual Report June 2022

ESGTI AG

## Table of Contents

Chairman's note.....	3
Investment context and ESG.....	4
Interim financial statements.....	5
Investors information.....	19

### Publication date

This report was released for publication on 29 Aug 2022.  
Amounts in this report are stated in Swiss Francs ("CHF") unless otherwise stated.

### Disclaimer

This document is for information only and is not an offer to sell or an invitation to invest. In particular, it does not constitute an offer or solicitation in any jurisdiction where it is unlawful or where the person making the offer or solicitation is not qualified to do so or the recipient may not lawfully receive any such offer or solicitation. It is the responsibility of any person in possession of this document to inform themselves of, and to observe all applicable laws and regulations of relevant jurisdictions.

All statements contained herein that are not historical facts including, but not limited to, statements regarding anticipated activity are forward looking in nature and involve a number of risks and uncertainties. Actual results may differ materially. Readers are cautioned, not to place undue reliance on any such forward-looking statements, which statements, as such, speak only as of the date made.



## Chairman's note

The first half of 2022 has been a tumultuous time for many; with disruptive events exposing vulnerabilities to the security of raw materials, energy supplies and basic food provisions. As a company focused on investing in life's fundamentals, the fragility of our systems is not news to us; but these events still remind us of the scale and urgency of the challenges we face.

Russia's invasion of Ukraine has shown us a new timeline; one of disruption. In addition to responding to the human tragedy, companies are now reckoning with supply insecurities, deglobalization and employee precarity. Some firms and governments are scrambling to find secure sources of energy and base commodities, leading to decisions that could affect near-term progress on sustainability. Others must consider pausing the fight for more resilient, sustainable food systems to focus on serving imminent demands.

Fortunately for ESGTI, sustainable systems are both our goal and our backbone. The year started successfully with a positive change in our NAV in January, above all reflecting key development milestones and sector aptitude in our Clean Energy pillar. As the energy landscape continued to face large-scale disruption, we continued to monitor the energy sector, understanding and evaluating new opportunities in a changing and critical space. We are also proud to share that Salvatore Toscano – Eko Agro Group's CEO, was invited to the Italian AgriTech Investor Day to share how technologies and synergies can be leveraged to overhaul food systems in Italy; exploring the productive realities of the current agri-food industry and investigating how food production and energy supplies can co-exist in the AgriTech sphere.

As we continue to operate within global disruption, we remain steadfast in evaluating our ESG impact and investing in an experienced and adaptive team. We expanded our Board and recently welcomed two subsequent new Board members Dr. Jessica Kourniaktis and Mr. Jörg Zulauf whose elections will strengthen the diversity and experience of our leadership team.

We look forward to sharing our results with you,

Hünenberg, August 2022, Andreas R. Bihrer, Chairman



## ESGTI: Today's investment context

As we speak of global disruption, it is fitting that we take a brief look at our investment sectors in today's context. Climate remains high on agendas everywhere; recently echoed in the signing of the US Inflation Reduction Act which contains \$369 billion in funding to build clean-energy infrastructure, accelerate the EV transition, improve energy efficiencies, and ensure environmental justice. The backdrop in Europe is equally broad, albeit faced with the immediate strain of energy supplies to its members.

One sub-section of solutions, namely Climate Tech, is traditionally defined as technologies that are explicitly focused on reducing GHG emissions or addressing the impacts of global warming. Its start-up ecosystem is currently worth more than \$100 billion and aggressive growth predictions can be found from most analysts. With energy and carbon emissions often symbiotic, we continue to focus on the field of wind power (both generation and mechanical efficiencies), photovoltaic (placement and harvesting) and piezoelectricity (conversion and implementation) to serve both evolutionary and revolutionary approaches to our energy transition.

Sustainability is ultimately an interconnected topic, and we seek to leverage this. The evolution of energy and food production in tandem through commercially active agri-voltaics systems allows us to invest in both energy and agriculture. As the plastic waste generated by healthcare reaches new levels from the Covid-19 fallout, we invest in medical devices designed for reuse and kept in circulation for as long as is feasible, minimising environmental waste while delivering social impact. Similarly, as the number of IoT devices reaches tens of billions of units and the associated battery waste becomes more prevalent, piezoelectric harvesting has a potential of making IoT devices maintenance-free and perpetually powered, including those used over the horizon in AgriTech.

During the last two years ESGTI has undertaken an assessment of its operational ESG rating. Our goal is to evaluate our performance by independent raters to understand how we're doing, how to improve, and offer investors a transparent view. We focus on early-stage companies, which always creates a challenge with respect to data gathering, which is why we collaborate with our independent raters to understand comparative benchmarks and sector-specific performance. We are happy to share top line results below, with the full Report available on our website.



## Statement of comprehensive income (unaudited)

(all amounts in CHF unless otherwise stated)

	Note	01.01.2022-30.06.2022	01.01.2021-30.06.2021
Net change in value of investments through profit or loss	3	2,261,624	934,181
Unrealised gain on loan receivable at fair value through profit or loss	6	1,797,193	2,878,301
<b>Result from investments</b>		<b>4,058,818</b>	<b>3,812,482</b>
Investment advisory fees		-495,957	-470,692
Directors Fees		-138,320	-53,560
Administration fees		-53,739	-68,900
Legal fees		-58,968	-171,557
Audit fees		-90,735	-120,281
Equity and debt issuance related costs		-80,018	-19,036
Financial income		88,116	53,021
Other administrative and operational expenses		-83,687	-116,673
<b>Operating result before financial result and taxes</b>		<b>3,145,509</b>	<b>2,844,805</b>
FX gain / loss		-69,113	16,046
Financial expenses		-1,689,568	-2,441,439
Proportionate result of Associate	4	-44,256	84,021
<b>Earnings before tax</b>		<b>1,342,572</b>	<b>503,432</b>
Income taxes	11	-	-
<b>Net result for the period</b>		<b>1,342,572</b>	<b>503,432</b>
<b>Total comprehensive income attributable to:</b>			
Shareholders		1,342,572	503,432
<b>Earnings per share attributable to Shareholders</b>			
Weighted average number of shares outstanding during the period		25,985,369	24,822,942
Basic earnings per share (CHF)		0.05	0.02
<b>Diluted earnings per share attributable to Shareholders</b>	2.6		
Weighted average number of outstanding and potential shares outstanding during the period		34,530,702	38,701,609
Diluted earnings per share (CHF)		0.08	0.05

The accompanying notes form an integral part of these financial statements.

## Balance sheet (unaudited)

all amounts in CHF unless otherwise stated

	Notes	30.06.2022	31.12.2021
<b>Assets</b>			
<b>Current assets:</b>			
Cash and cash equivalents		10,105	8,205
Receivables and other assets	7	1,346,275	1,986,778
<b>Total current assets</b>		<b>1,356,380</b>	<b>1,994,982</b>
<b>Non-current assets:</b>			
Current accounts with investments	5	33,053,578	32,712,735
Investment in Associate	4	522,524	566,780
Investments at fair value through profit and loss	3	111,297,103	109,035,479
Loan receivable	6	62,184,408	60,387,215
<b>Total non-current assets</b>		<b>207,057,613</b>	<b>202,701,109</b>
<b>Total assets</b>		<b>208,413,993</b>	<b>204,697,191</b>
<b>Liabilities</b>			
<b>Current liabilities:</b>			
Accrued expenses and other payables	8	5,384,972	4,541,010
Short-term financial liabilities	9	10,462,569	8,956,651
Provisions direct taxes		132,559	108,209
<b>Total current liabilities</b>		<b>15,980,101</b>	<b>13,605,871</b>
<b>Non-current liabilities:</b>			
Long term financial liabilities	9	51,272,000	51,272,000
<b>Total non-current liabilities</b>		<b>51,272,000</b>	<b>51,272,000</b>
<b>Equity</b>			
<b>Shareholders' equity:</b>	10		
Share capital		40,537,176	40,537,176
Capital reserves		50,289,300	50,289,300
Retained earnings		48,992,844	8,117,030
Result of the period		1,342,572	40,875,814
<b>Total shareholders' equity</b>		<b>141,161,893</b>	<b>139,819,320</b>
<b>Total liabilities and shareholders' equity</b>		<b>208,413,993</b>	<b>204,697,191</b>
Number of outstanding shares		25,985,369	25,985,369
Net asset value (NAV) per share (CHF)	2.7	5.43	5.38

The accompanying notes form an integral part of these financial statements.

## Statement of cash flows (unaudited)

(all amounts in CHF unless otherwise stated)

	Note	01.01.2022-30.06.2022	01.01.2021-30.06.2021
Proceeds from sale of investment		732,823	-
Expenses paid (administrative and other operating expenses)		-352,439	-153,193
Loans repaid / financing provided		-400,304	-433,311
Loans granted		-	-
<b>Net cash flows from operating activities</b>		<b>-19,920</b>	<b>-586,504</b>
Interest paid		-230,630	-2,387,511
Loans received		252,477	2,985,003
Bonds issued		-	-
<b>Net cash flows from financing activities</b>		<b>21,846</b>	<b>597,492</b>
Currency translation differences on cash and cash equivalents		-26	-1,417
<b>Net change in cash and cash equivalents</b>		<b>1,900</b>	<b>9,571</b>
Cash and cash equivalents at beginning of period		8,205	49,823
Cash and cash equivalents at end of period		10,105	59,394

The accompanying notes form an integral part of these financial statements.

## Statement of changes in equity (unaudited)

(all amounts in CHF unless otherwise stated)

	Note	Share capital	Capital reserve	Retained earnings	Total shareholders' equity
<b>Balance as per 1 January 2021</b>		<b>33,875,757</b>	<b>39,870,159</b>	<b>8,117,031</b>	<b>81,862,946</b>
Comprehensive result				503,432	503,432
Capital increase		6,661,419	10,419,142		17,080,561
<b>Balance as per 30 June 2021</b>		<b>40,537,176</b>	<b>50,289,300</b>	<b>8,620,463</b>	<b>99,446,939</b>
<b>Balance as per 1 January 2022</b>		<b>40,537,176</b>	<b>50,289,300</b>	<b>48,992,844</b>	<b>139,819,320</b>
Comprehensive result				1,342,572	1,342,572
<b>Balance as per 30 June 2022</b>		<b>40,537,176</b>	<b>50,289,300</b>	<b>50,335,417</b>	<b>141,161,893</b>

The accompanying notes form an integral part of these financial statements.



## Notes to the consolidated condensed interim financial statements (unaudited)

### 1. Organisation and business activity

ESGTI Ltd. ("ESGTI" or the "Company") is domiciled at Rothusstrasse 21, Hünenberg, Switzerland.

ESGTI's investment objective is to provide shareholders with long term capital growth by investing in or financing, directly or through investment companies, early-stage companies or projects with transformative impact objectives. Investments may include investments in private equity and private equity related instruments and opportunistically in certain categories of credit products. Net profits generated upon realizations will typically be re-invested.

### 2. Summary of accounting policies for the financial statements

The significant accounting policies adopted in the preparation of these condensed interim financial statements ("Interim Financial Statements", "IFS") are set out below. The Interim Financial Statements comprise ESGTI, and the non-consolidated investments in (i) ESG LifeSciences Ltd., Hünenberg, Switzerland ("ESG-LS"), (ii) ESG EKO AGRO GROUP s.r.l., Bologna, Italy ("ESG EA IT"), (iii) Sky Energy Ltd, Hünenberg, Switzerland ("Sky"), (iv) AltEnergis plc, London, United Kingdom ("AltEnergis"). The non-consolidated investee companies are referred to as Investment or Investments respectively if not addressed by name.

ESGTI further holds a minority equity stake in ESG Engineering & Consulting Ltd., Zürich, Switzerland ("ESG E&C"). ESG E&C acts as the investment advisor of ESGTI and is accounted for at equity, see note 2.7. ESG E&C is referred to as Associate or Investment Adviser if not addressed by name.

#### 2.1. Basis of preparation

The Interim Financial Statements as per 30 June 2021 have been prepared in accordance with IAS 34 Interim Financial Reporting of the International Financial Reporting Standards ("IFRS") as published by the International Accounting Standards Board ("IASB").

These Interim Financial Statements do not include all the information and disclosures required in annual financial statements. Accordingly, this report is to be read in conjunction with the annual report for the year ended 31 December 2021. Unless indicated otherwise, the values are in Swiss Francs ("CHF"); the reporting and functional currency of the Company.

#### 2.2. New or amended standards and interpretations applied for the first time during the year under review

These Interim Financial Statements are interim financial statements covering the period from 1 January 2022 to 30 June 2022.

ESGTI complies with the standards and amendments to published standards that are mandatory for the financial year beginning on or after 1 January 2022. There are no standards, amendments to standards or interpretations that are effective for annual periods beginning on 1 January 2022 that have a material effect on the financial statements of the Company.

A number of new standards, amendments to standards and interpretations are effective for annual periods starting on or after 1 July 2022 and have not been early adopted in preparing these financial statements. None of these are expected to have a material effect on the financial statements of the Company.

### 2.3. Significant accounting judgements, estimates and assumptions

The preparation of the Group Financial Statements requires the Board of Directors to make estimates which affect reported earnings, expenditure, assets, liabilities, and investment commitments as at the balance sheet date. If the estimates made by the Board of Directors to the best of their knowledge at the balance sheet date are subsequently shown to differ from actual circumstances, the original estimates will be adjusted accordingly during the reporting year in which circumstances have changed.

A high degree of uncertainty is attached specifically to estimating the fair value of the Investments as those Investments are in private companies and funds which are not actively traded. The fair value of investments that are not traded in an active market are determined by using appropriate methods in accordance with the valuation policies. The use of valuation techniques requires estimates made by the Board of Directors. Changes in assumptions could affect the disclosed fair value of these investments. Valuation policies are disclosed in the latest annual financial statements.

### 2.4. Foreign currencies

The functional currency for the Company is the Swiss Franc ("CHF"). Transactions in foreign currencies are accounted for at the exchange rate on the date of the transaction. Monetary assets and liabilities in foreign currencies are converted into Swiss francs at the exchange rates prevailing on the balance sheet date. The resulting foreign currency gains or losses are accounted for through profit and loss.

The following exchange rates were used in the preparation of these Interim Financial Statements:

	30.06.2022	31.12.2021
<u>Exchange rates to CHF</u>		
EUR	1.0008	1.0367
USD	0.9551	0.9122
GBP	1.1625	1.2338

### 2.5. Significant accounting policies

#### 2.5.1. Investments

##### Investments in private companies and their valuation

The Company's investments in private companies are presented as non-current financial assets. ESGTI currently only holds investments not traded on an active market. Such investments are either held directly or indirectly through fully owned investment companies. Investments held directly are governed by the Board of Directors where ESGTI has engaged ESG E&C as its investment advisor. Investments held indirectly are governed by the Board of Directors of the corresponding investment company as advised by their investment advisors.

The investments are initially recognised at fair value and subsequently carried at fair value through profit or loss. If an investment is in a very early stage, this transaction is carried at the transaction price which is considered the closest approximation to fair value.

The responsibility for determining the fair values lies with the Board of Directors. While the investment advisors of either ESGTI or the investment companies provide valuations of these investments, the Board of Directors reviews and discusses these valuations initially as at the purchase date and subsequently at least annually. Adjustments to the reported values are performed by the Board of Directors when considered necessary, especially when the Board of Directors is aware of any significant fact that is not or not fully reflected in the valuations.

The basis of the Investment Advisor's valuation is usually a third-party valuation of the investment. If no third-party valuation was performed, the valuation is performed by the Investment Advisor using suitable valuation techniques. Valuations by a third party and by the Investment Advisor are usually based upon a discounted cash flow ("DCF") with the usage of observable inputs wherever possible.

The Investment Advisor adjusts this basis of valuation using the International Private Equity and Venture Capital Valuation (IPEV) guidelines. The most important valuation factors are technology validation, last prices paid, market potential and the position within the market, and the experience and performance of the management of the investment. The original costs or the subsequent capital increase price is considered an approximation of the fair value at the time of the transaction.

#### Current accounts with Investments (loans receivable)

ESGTI may finance its Investments and recognize a receivable from such loans, presented as current accounts with Investments on the balance sheet. The Investments consequently have a liability towards ESGTI. Any liability of such Investments is fully taken into account when the fair value of the Investment is determined. The objective of these loans is to collect the contractual cash flows which are solely payments of principal and interest, scheduled collection date is at the latest the exit date of the Investment. The current accounts with Investments are valued at amortised costs. ESGTI applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance.

#### Recognition of additions and disposals

All purchases and sales of investments in companies, investment companies and funds are recognised on the settlement date, i.e., on the date on which the assets are delivered to ESGTI and ESGTI is the future beneficiary of the Investment and has an obligation to settle the purchase price.

#### Realised and unrealised gains / losses

The impact from the fair valuation is presented in the statement of comprehensive income as the net change in value of investments through profit and loss. When an Investment is sold the "Realised gains or losses on investments" is disclosed separately. It is calculated as the difference between the sale proceeds of an investment and the capital invested. Unrealised gains and losses recorded in previous years on investments sold are eliminated and, together with the value adjustments on investment holdings for the current fiscal year, are reported under "Changes in unrealised gains and losses".

#### 2.5.2. Loan receivable

ESGTI agreed on a long-term financing, due in financial year 2030. ESGTI's purpose, as an investment company, in entering into the loan is to maximise fair value gains and to generate value. Under IFRS 9, the loan receivable is therefore valued at fair value through profit or loss.

For private debt valuation models, the Company considers the original transaction price, recent transactions in the same or similar instruments, and completed third-party transactions for comparable instruments, and it adjusts the model as deemed necessary.

### 2.5.3. Other accounting policies

All other accounting policies are disclosed in the latest annual financial statements and were also applied in these Interim Financial Statements.

## 2.6. Earnings per share

Earnings per share are calculated by dividing the net result for the year that is due to shareholders by the time-weighted average number of shares in circulation during the same period.

Diluted earnings per share are calculated by dividing the net result for the year adjusted for income related to potential outstanding shares that is due to shareholders by the sum of the time-weighted average number of shares in circulation during the same period, adjusted for costs and for the potential issue of new shares in connection with outstanding convertible bonds, share options and similar instruments if those costs are material.

	Note	30.06.2022	30.06.2021
<b>Diluted earnings per share</b>			
Net result for the period		1,342,572	503,432
Adjusted for interest savings on convertible bonds	9	1,459,071	1,367,528
Adjusted net result for the period		2,801,644	1,870,960
Weighted average number of ordinary shares outstanding		25,985,369	24,822,942
Adjustments for potential shares outstanding for convertible bonds	9	8,545,333	13,878,667
Total of ordinary and potential shares outstanding		34,530,702	38,701,609
<b>Diluted earnings per share</b>		<b>0.08</b>	<b>0.05</b>

## 2.7. Net asset value

The net asset value per share ("NAV", "NAV per share") is calculated from the shareholders' equity reported as at the balance sheet date, divided by the number of shares outstanding on that date.

## 2.8. Segment reporting

ESGTI's business purpose is the long-term capital growth for shareholders under the consideration of Impact / ESG principles. The portfolio is managed as a whole on a fair value basis and therefore is only one operating segment.



### 3. Investments

Name, Domicile	Note	Purchase	Cost (kCHF)	Fair Value (kCHF) (31.12.21)	Fair Value (kCHF) (30.06.22)	gain/ loss(-) (current period)	gain/ loss(-) (since purchase)	latest valuation year and method
ESG LifeSciences Ltd, CH	3.1	2020	29,300	13,963	8,504	-5,459	-20,796	2022 - NAV
Investments held								
SynDermix Ltd, CH		2018		42,342	37,424			2021- DFC
Enielle Ltd, CH		2019		752	276			2021- Revenue multiple
Rheon Medical SA, CH		2020		617	617			2021- latest capital increase
ESG Eko Agro Group s.r.l., IT	3.2	2020	-	3,506	3,771	266	3,771	2021- tax valuation (adjusted)
AltEnergis plc, UK	3.3	2020	23,701	91,267	98,752	7,485	75,051	2021- DCF
SkyEnergy Ltd, CH	3.4	2020	400	300	269	-31	-131	2020 - latest transaction price
<b>Total</b>			53,401	109,035	111,297	2,262	57,896	

For the current period, the company presents a net change in value of investments through profit or loss amounting to CHF 2,261,624. This change is based on the fair value increase of AltEnergis (+ CHF 7.5m) and ESG Eko Agro Group (+ CHF 0.3m) and a fair value decrease of the investment in ESG LifeSciences (- CHF 5.5m).

#### 3.1. ESG LifeSciences Ltd., Hünenberg, Switzerland

ESG LifeSciences Ltd. is a Swiss investment company with registered office in Hünenberg, Switzerland focusing on investments in the life sciences and advised by Dragon Finance Ltd, Zurich, Switzerland.

100% of the shares of ESG-LS were purchased on 1 January 2020. ESG-LS is invested in three companies:

- SynDermix Ltd., Stans, Switzerland, a Swiss developer of innovative health technologies funded by private investors. The company focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs. As of 30 June 2022, ESG-LS held 64.6% of SynDermix AG (31 December 2021: 64.6%).
- Énielle Ltd., Zürich, Switzerland, a Swiss developer of nature-based cosmeceuticals, 80% owned by ESG-LS as per 30 June 2022 (31 December 2021: 80%).
- Rhéon Medical SA, Préverenges, Switzerland, a privately held Swiss medical device company, a spin-off from the Swiss Federal Institute of Technology Lausanne. As per 30 June 2022, ESG-LS held 3.19% of Rhéon Medical SA (31 December 2021: 3.19%).

#### 3.2. ESG Eko Agro Group s.r.l., Bologna, Italy

ESG Eko Agro Group s.r.l. is an Italian investment company focusing on agricultural and energy projects. As per 30 June 2022, the company was 66.6% owned by ESGTI (31 December 2021: 66.6%).

### 3.3. AltEnergis plc, London, UK

AltEnergis plc is a UK-based, privately funded technology development and commercialisation company.

ESGTI holds 100% of AltEnergis as per 30 June 2022 (31 December 2021: 100%).

### 3.4. Sky Energy Ltd, Hünenberg, Switzerland

Sky Energy Ltd is a Swiss-based energy company with the purpose to acquire and operate renewable energy parks and to supply the generated wind- and solar energy to commercial and residential customers. As per 30 June 2022, ESGTI holds 100% of Sky (31 December 2021: 100% of Sky).

## 4. Investment in Associate

ESG Engineering & Consulting Ltd. is a Swiss company with registered office in Zurich, Switzerland. ESG E&C is the Investment Advisor for ESGTI, ESGTI holds 40% of ESG E&C as per 30 June 2022 and as per 31 December 2021.

	30.06.2022	31.12.2021
<b>Associated company at equity:</b>		
ESG Engineering & Consulting Ltd., Zurich, Switzerland, voting/capital rights: 40%		
Purchase price	200,000	200,000
Accumulated proportionate result until beginning of the current period	366,780	124,183
Proportionate result of the current period (comparative: full financial year)	-44,256	242,597
<b>Total associated company</b>	<b>522,524</b>	<b>566,780</b>

## 5. Current accounts with Investments and Associate

ESGTI has current accounts with its Investments and its Associate. Details and movements of these accounts are outlined below.

All current accounts are unsecured. All current accounts with Investments are subject to interest of 7.1% as per 30 June 2022 except the current account with ESG LifeSciences which is subject to 0.25% interest. The current accounts are repayable on demand.

	2022	2021
<b>Current accounts with Investments</b>		
<b>ESG LifeSciences Ltd</b>		
As per 1.1.	31,502,568	13,243,210
Increase / (-)decrease	108,929	18,259,357
<b>As per 30.06. / 31.12.</b>	<b>31,611,497</b>	<b>31,502,568</b>
<b>ESG Eko Agro Group s.r.l</b>		
As per 1.1.	744,724	281,619
Increase / (-)decrease	188	463,105
<b>As per 30.06. / 31.12.</b>	<b>744,912</b>	<b>744,724</b>
<b>AltEnergis plc</b>		
As per 1.1.	453,497	245,052
Increase / (-)decrease	231,726	208,445
<b>As per 30.06. / 31.12.</b>	<b>685,223</b>	<b>453,497</b>
<b>Sky Energy Ltd</b>		
As per 1.1.	11,947	350
Increase / (-)decrease	-	11,597
<b>As per 30.06. / 31.12.</b>	<b>11,947</b>	<b>11,947</b>
<b>Total current accounts with Investments</b>	<b>33,053,578</b>	<b>32,712,735</b>

## 6. Loan receivable

	30.06.2022	31.12.2021
<b>Loan receivable</b>		
Loan receivable at cost	49,632,386	49,632,386
Unrealised gain on loan receivable	12,552,022	10,754,829
<b>Total loan receivable</b>	<b>62,184,408</b>	<b>60,387,215</b>

The loan receivable matures as per 31 October 2030 and is held at fair value through profit or loss. The loan is subject to 6.75% interest, the first interest payment is due as per 3 January 2025 with subsequent annual interest payments.

Unrealised gain on loan receivable of CHF 12.6m comprise of an unrealised gain amounting to CHF 1.8m for the current period as disclosed in the statement of comprehensive income and unrealised gain amounting to CHF 10.8m related to prior periods.

## 7. Receivables and other assets

	30.06.2022	31.12.2021
<b>Receivables and other assets</b>		
Receivables from third parties	1,346,275	1,986,778
<b>Total receivables and other assets</b>	<b>1,346,275</b>	<b>1,986,778</b>

## 8. Accrued expenses and other payables

	30.06.2022	31.12.2021
<b>Accrued expenses and other payables</b>		
Payables to and accruals for service providers	-1,799,373	-2,679,408
Payables to governmental institutions	-213,951	-133,932
Payables and accruals for Investment Advisor	-2,604,407	-1,329,244
Accruals for directors' fees	-528,080	-389,760
Other accruals and payables	-239,161	-8,665
<b>Total payables</b>	<b>-5,384,972</b>	<b>-4,541,010</b>

## 9. Financial liabilities

	30.06.2022	31.12.2021
<b>Financial liabilities</b>		
Short-term loan from shareholder	-2,696,188	-2,418,712
Short-term loan from others	-3,628,606	-3,628,606
Interest payable from bonds issued	-4,137,774	-2,909,333
<b>Financial liabilities payable within 12 months</b>	<b>-10,462,569</b>	<b>-8,956,651</b>
Long-term loan from bonds issued	-51,272,000	-51,272,000
<b>Financial liabilities payable after 12 months</b>	<b>-51,272,000</b>	<b>-51,272,000</b>

All financial liabilities are measured at amortised cost.

Short-term loan from shareholder and short-term loan from others are current accounts for financing purposes with shareholders and third parties.

The long-term loan from bonds issued is a tradeable bond, identified with ISIN XS2158598354. The semi-annually payable interest is 5.75%, payment dates are end of April / end of October each year until maturity. ESGTI offered a buyback of the bonds issued, to be settled in the second half-year of 2022.

## 10. Shareholders' equity

### 10.1. Share capital and capital reserves

The Company's share capital amounts to CHF 40.5 million, divided into 25,985,369 registered shares at a par value of CHF 1.56 each. All shares are authorised, issued and fully paid-up (31 December 2021:



CHF 40.5 million share capital, 25,985,369 registered shares, par value CHF 1.56, authorised, issued and fully paid-up).

Capital reserves of the Company amount to CHF 50.2 million (31 December 2021: CHF 50.2 million). Pending approval from Swiss tax authorities, capital reserves are withholding tax exempt when distributed to the shareholders.

## 10.2. Significant shareholders

The following major shareholders were known by the Company at balance sheet date:

	30.06.2022	30.12.2021
More than 20%	Fund Advisers (Cayman) SPC obo Aspect Capital SP; George Town, Cayman Islands	Fund Advisers (Cayman) SPC obo Aspect Capital SP; George Town, Cayman Islands
Between 10% and 20%	-	-
Between 5% and 10%	WP Multi Strategy Fund; George Town, Cayman Islands	WP Multi Strategy Fund; George Town, Cayman Islands
Below 5% (free float)	57.60%	57.60%

## 11. Taxes

Income taxes for the reporting and the comparative period are zero as it is considered unlikely that the Company will generate income subject to income taxes. Presented tax provisions for direct taxes are accruals for capital taxes.

## 12. Related party transactions

	01.01.2022-30.06.2022	01.01.2021-30.06.2021
<b>Related party transactions</b>		
<b>Remuneration of the Board of Directors</b>		
Chairman	30,000	30,000
Members	100,000	60,000
Waiver of board fee	-	-40,000
Related social security expenses	8,320	-
<b>Investment Advisor ESG Engineering &amp; Consulting Ltd</b>		
Investment and performance fees	336,915	365,067
downpayments on open invoices	-167,689	-370,570
<b>Transactions with Investments</b>		
Financing provided to Investments	410,357	807,273
Sale of SynDermix shares to ESG-LS	-	17,080,560
<b>Transactions with Shareholders</b>		
Financing received from shareholders	277,477	297,161

Related parties are individuals and companies where the individual or company has the ability, directly or indirectly, to control the other party or to exercise significant influence over the other party in making financial

or operational decisions. All related party transactions have been carried out within the normal course of business.

Remuneration of the Board of Directors comprise the agreed fees to the members of the Board of Directors, social security contributions are presented separately.

### 13. Subsequent events

Since the balance sheet date of 30 June 2022 there have been no material events that could impair the integrity of the information presented in these financial statements.

## Investors information

Shares	Listing
ISIN CH0298294981	BX Swiss
Valor 29829498	
WKN A1409X	Publication of net asset value
Ticker ESGTI	<a href="http://www.esgti.com">www.esgti.com</a>

### Registered office

ESGTI AG; Rothusstrasse 21, CH-6331 Hünenberg, Switzerland

Telephone +41 41 500 99 83

### Board of Directors

Andreas R. Bihrer, Attorney at Law, Zurich, Switzerland (Chairman)

Brunella Pavesi, PhD, Rome, Italy

Dimitri Dimitriou, MSc, FRSC, FRSB, FIBMS, Freienbach, Switzerland

Kourniaktis, Jessica, DPhil, Zurich, Switzerland (since 27 July 2022)

Kimberley Marty, BSc, Dübendorf, Switzerland

Wolfgang Werlé, BA, Zumikon, Switzerland

Hermann Wirz, BA, Pully, Switzerland

Zulauf, Jörg, lic.iur, MBA, Thalwil, Switzerland (since 27 July 2022)

### Auditor

PricewaterhouseCoopers AG, Birchstrasse 160, Zurich, Switzerland

### Investment Advisor

ESG Engineering & Consulting AG, Spyristrasse 11, 8044 Zurich, Switzerland

Manage Mind AG, Voltastrasse 61, 8044 Zurich, Switzerland

### Administrator

ARIA Fund Services, Office 1004, Park Place Tower, Sheikh Zayed Road, Dubai, United Arab Emirates